Also found in: Dictionary, Thesaurus.
Related to enalaprilat: Fenoldopam, Pivampicillin


an angiotensin-converting enzyme inhibitor, the active metabolite of enalapril, administered intravenously in the treatment of hypertensive crisis or when oral administration of enalapril maleate is impractical.


Vasotec IV

Pharmacologic class: Angiotensin-converting enzyme (ACE) inhibitor

Therapeutic class: Antihypertensive

Pregnancy risk category C (first trimester), D (second and third trimesters)

Pregnancy risk category C (first trimester), D (second and third trimesters)

FDA Box Warning

• When used during second or third trimester of pregnancy, drug can cause fetal injury and even death. Discontinue as soon as pregnancy is detected.


Inhibits conversion of angiotensin I to angiotensin II, a potent vasoconstrictor; inactivates bradykinin and prostaglandins. Also increases plasma renin and potassium levels and reduces aldosterone levels, resulting in systemic vasodilation.


Injection: 1.25 mg/ml

Tablets: 2.5 mg, 5 mg, 10 mg, 20 mg

Indications and dosages


Adults: For patients not taking concomitant diuretics-initially, 5 mg P.O. once daily, increased after 1 to 2 weeks as needed to a maintenance dosage of 10 to 40 mg P.O. daily given as a single dose or in two divided doses; or 1.25 mg I.V. q 6 hours. For patients taking diuretics-initially, 2.5 mg P.O. or 0.625 mg I.V.

Children: 0.08 mg/kg P.O. once daily; may be increased based on blood pressure response up to 5 mg daily. Maximum dosage is 0.58 mg/kg/dose.

Heart failure

Adults: Initially, 2.5 mg P.O. once or twice daily, increased after 1 to 2 weeks as needed to maintenance dosage of 5 to 40 mg P.O. daily given as a single dose or in two divided doses

Asymptomatic left ventricular dysfunction

Adults: Initially, 2.5 mg P.O. once or twice daily, increased after 1 to 2 weeks as needed to a maximum of 20 mg/day in divided doses

Dosage adjustment

• Renal impairment

Off-label uses

• Diabetic nephropathy
• Hypertensive emergency


• Hypersensitivity to drug or other ACE inhibitors
• Angioedema
• Pregnancy


Use cautiously in:
• renal or hepatic impairment, hypovolemia, hyponatremia, aortic stenosis, hypertrophic cardiomyopathy, cerebrovascular or cardiac insufficiency
• concurrent diuretic use
• elderly patients
• breastfeeding patients
• children.


• Give oral doses with food or beverage.
• Discontinue diuretics for 2 to 3 days before starting drug, if possible.
• Know that I.V. administration is usually reserved for patients who cannot take P.O. form.
• Be aware that I.V. administration isn't recommended for pediatric patients.
• Administer I.V. dose either undiluted or diluted in 50 ml of dextrose 5% in water, normal saline solution, dextrose 5% in normal saline solution, or dextrose 5% in lactated Ringer's solution.
• Give single I.V. dose by push or piggyback over 5 minutes. If patient is at risk for hypotension, infusion may be given over 1 hour.
• Be aware that black patients have a higher risk of angioedema.

Adverse reactions

CNS: dizziness, fatigue, headache, insomnia, drowsiness, vertigo, asthenia, paresthesia, ataxia, confusion, depression, nervousness,cerebrovascular accident

CV: orthostatic hypotension, palpitations, angina pectoris, tachycardia, peripheral edema,arrhythmias, cardiac arrest

EENT: sinusitis

GI: nausea, vomiting, constipation, dyspepsia, abdominal pain, dry mouth, pancreatitis

GU: proteinuria, urinary tract infection, erectile dysfunction, decreased libido,oliguria

Hematologic: agranulocytosis, bone marrow depression

Hepatic: hepatitis

Metabolic: hyponatremia,hyperkalemia Respiratory: cough, upper respiratory tract infection, asthma, bronchitis, dyspnea,eosinophilic pneumonitis

Skin: rash, alopecia, photosensitivity, diaphoresis, exfoliative dermatitis, angioedema,erythema multiforme

Other: altered taste, fever, increased appetite, anaphylactoid reactions


Drug-drug.Allopurinol: increased risk of hypersensitivity reaction

Antacids: decreased enalapril absorption Cyclosporine, indomethacin, potassiumsparing diuretics, potassium supplements: hyperkalemia

Digoxin, lithium: increased blood levels of these drugs, possible toxicity

Diuretics, nitrates, other antihypertensives, phenothiazines: additive hypotension

Nonsteroidal anti-inflammatory drugs: decreased antihypertensive response

Rifampin: decreased enalapril efficacy

Drug-diagnostic tests.Alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, bilirubin, blood urea nitrogen (BUN), creatinine, potassium: increased levels Antinuclear antibodies: positive titer Sodium: decreased level

Drug-food.Salt substitutes containing potassium: hyperkalemia

Drug-herbs.Capsaicin: increased incidence of cough

Drug-behaviors.Acute alcohol ingestion: additive hypotension

Sun exposure: photosensitivity reaction

Patient monitoring

Assess for rapid blood pressure drop leading to cardiovascular collapse, especially when giving with diuretics.

In patient with renal insufficiency or renal artery stenosis, monitor for worsening renal function.
• After initial dose, observe patient closely for at least 2 hours until blood pressure has stabilized. Then continue to observe for additional hour.
• Monitor vital signs, fluid intake and output, and daily weight.
• Supervise patient during ambulation until effects of drug are known.
• Monitor liver function tests, BUN, and creatinine and electrolyte levels.

Patient teaching

• Inform patient that drug's full effect may not occur for several weeks.
• Advise patient to report persistent dry cough with nasal congestion.

Tell patient to immediately report swelling of face, eye area, tongue, lips, hands, or feet; rash, hives, or severe itching; unexplained fever; unusual tiredness; yellowing of skin or eyes; abdominal pain; or easy bruising.
• Instruct patient to move slowly when sitting up or standing, to avoid dizziness or light-headedness from sudden blood pressure decrease.
• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, foods, herbs, and behaviors mentioned above.


/enal·a·pril·at/ (-pril-at″) an angiotensin-converting enzyme inhibitor, the active metabolite of enalapril, used to treat hypertensive crisis and as an intravenous substitute for oral enalapril maleate.


the pharmacologically active product of hepatic hydrolysis of enalapril.
References in periodicals archive ?
Commercial distribution of both enalaprilat injection and enalapril maleate tablets will commence immediately.
The patent relates to a method for delivering a therapeutically effective amount of enalaprilat, the pharmaceutically active form of the drug enalapril, by means of transdermal drug delivery systems (patches).
1mcg nitroglycerin 5-100 mcg/min continuous IV nicardipine 10-15 mg/hr hydrochloride continuous IV (Cardene) enalaprilat (Vasotec) 1.
International pharmaceutical and health care company, F H Faulding & Co Limited (Faulding), today announced that its Faulding Pharmaceuticals division has received final approval from the Food and Drug Administration (FDA) in the United States for its abbreviated new drug application (ANDA) for enalaprilat injection, following the expiry of the paediatric exclusivity period on 22 August 2000.
The three other approvals include the final approval for labetalol HCI and cytarabine 2g/20mL during November 1999 and December 1999 respectively, and the tentative approval for enalaprilat injection in February 2000.